Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia [2]

Leukemia and Lymphoma

Volumn 47, Issue 7, 2006, Pages 1394-1396

  Piccin, Andrea ^a   Conneally, Eibhlin ^a   Lynch, Margareth ^a   McMenamin, M E ^a   Langabeer, Stephen ^a   McCann, Shaun ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB;

ADENOMATOID TUMOR; ADULT; BLADDER CANCER; BONE PAIN; CANCER PATIENT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DEPIGMENTATION; DRUG TOLERABILITY; FATIGUE; HUMAN; INFLAMMATORY INFILTRATE; KARYOTYPE 46,XY; KARYOTYPING; LETTER; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; NEPHROTOXICITY; PERIORBITAL EDEMA; PHYSICAL EXAMINATION; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; TESTIS BIOPSY; TESTIS TUMOR; TREATMENT OUTCOME; ULTRASOUND;

ADENOMATOID TUMOR; ADULT; ANTINEOPLASTIC AGENTS; HUMANS; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC; MALE; PIPERAZINES; PYRIMIDINES; TESTICULAR NEOPLASMS;

EID: 33747711326     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600556098     Document Type: Letter

References (9)

1. Breccia, M and D'Elia, G and D'Andrea, M and Latagliata, R and Alimena, G. (2005) Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. Eur J Haematol, 74, pp. 89-90.
2. Goldsby, R and Pulsipher, M and Adams, R and Coffin, C and Albritton, K and Wagner, L. (2002) Unexpected pleural effusions in 3 pediatric patients treated with STI-571. J Pediatr Hematol Oncol, 24, pp. 694-695.
3. Kitiyakara, C and Atichartakarn, V. (2002) Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant, 17, pp. 685-687.
4. Pou, M and Saval, N and Vera, M and Saurina, A and Sole, M and Cervantes, F and Botey, A. (2003) Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma, 44, pp. 1239-1241.
5. McPartlin, S and Leach, M. (2005) Loss of skin pigment caused by imatinib therapy. Br J Haematol, 129, pp. 448.
6. Roy, L and Guilhot, J and Martineau, G and Larchee, R and Guilhot, F. (2005) Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia, 19, pp. 1689-1692.
7. (2005) Novartis Periodic safety update report. SPUR
8. Pilot, P and Sablinska, K and Owen, S and Hatfield, A. (2006) Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia, 20, pp. 148.
9. Hughes, T and Kaeda, J and Branford, S and Rudzki, Z and Hochhaus, A and Hensley, M and (2003) International Randomised Study of Interferon vs STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytaraloine in newly diagnosed chronic myeloid leukemia. N Engl J Med, 349, pp. 1423-1432.